Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors40

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors24

Views

Views
January 20252
February 20253
March 202515
April 20253
May 20251
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States6
Spain1
United Kingdom1
Hong Kong1
 

Top cities views

Views
Buffalo2
Carlsbad1
Council Bluffs1
Hong Kong1